DUBLIN–(BUSINESS WIRE)–The “PCSK9 Inhibitors (PCSK9i) – Market Insights, Epidemiology, and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of PCSK9i, historical and forecasted epidemiology as well as the PCSK9 Inhibitors market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The PCSK9 Inhibitors market report provides disease areas, emerging drugs, PCSK9 Inhibitors market share of the individual therapies, current and forecasted PCSK9 Inhibitors market size from 2018 to 2030 segmented by seven major markets. The Report also covers current PCSK9 Inhibitors prescription eligibility criteria, approved and emerging therapies, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key Findings
In the year 2020, the total prevalent cases of Familial Hypercholestrolemia was 3.1 million cases in the 7MM which are expected to grow during the study period, i.e., 2018-2030.
The disease epidemiology covered in the report provides historical as well as forecasted Von Hippel-Lindau disease epidemiology [segmented as Total prevalent cases of Familial Hypercholesterolemia, Total diagnosed cases of Familial Hypercholesterolemia, Total type-specific cases of Familial Hypercholesterolemia, Total age group-specific cases of Familial Hypercholesterolemia, Total mutation-specific cases of Familial Hypercholesterolemia, Total risk factor-specific cases of PCSK9 Inhibitors in Prophylactic/Preventive setting, and Total Treated cases of PCSK9 Inhibitors] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Companies Mentioned
- Sanofi
- Regeneron Pharmaceuticals
- Amgen
- Novartis
- Alnylam Pharmaceuticals
- LIB Therapeutics
- AstraZeneca and Ionis Pharmaceuticals
- CiVi Biopharma
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the PCSK9 Inhibitors market.
- To understand the future market competition in the PCSK9 Inhibitors market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for PCSK9 Inhibitors in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the PCSK9 Inhibitors market.
- To understand the future market competition in PCSK9 Inhibitors market.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. PCSK9 Inhibitors Market Overview at a Glance
3.1. Market Share (%) Distribution of PCSK9 Inhibitors in 2018
3.2. Market Share (%) Distribution of PCSK9 Inhibitors in 2030
4. Executive Summary of PCSK9 Inhibitors (PCSK9i)
5. Key Events
5.1. Epidemiology and Market Methodology
6. PCSK9 Inhibitors (PCSK9i) Background and Overview
7. Introduction
7.1. PCSK9 gene biology
7.2. Functional mechanics of PCSK9
7.3. PCSK9 Inhibitors
7.4. PCSK9 Inhibition Strategies
7.5. The Approval Status of PCSK9 Inhibitors
7.6. Disease Areas of PCSK9 Inhibitors
7.6.1. Primary Hyperlipidemia
7.6.2. Prevention of Myocardial Infarction, Stroke, and Unstable Angina Requiring Hospitalization
8. Guidelines
8.1. ESC/EAS Guidelines for the Management of Dyslipidemias
8.2. American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
8.3. Recommendations From an Expert Panel of the National Lipid Association
8.4. Recommendations of the Spanish Society of Arteriosclerosis (SEA)
8.5. NICE guidelines
8.6. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases
8.7. Comparison of guidelines
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Epidemiology of PCSK9 Inhibitors
9.3. Epidemiology Scenario
9.3.1. Total Prevalent Cases of Familial Hypercholestrolemia
9.3.2. Total Diagnosed Cases of Familial Hypercholesterolemia
9.3.3. Total Type-specific Cases of Familial Hypercholesterolemia
9.3.4. Total Age-specific Cases of Familial Hypercholesterolemia
9.3.5. Total Mutation-specific Cases of Familial Hypercholesterolemia
9.3.6. Total Risk factor-specific Cases of PCSK9 Inhibitors in Prophylactic/Preventive setting
9.3.7. Total Treated Cases of PCSK9 Inhibitors
10. Patient Journey
11. Key Endpoints in PCSK9 inhibitor Clinical Trials
12. Marketed Drugs
12.1. Praluent (Alirocumab): Sanofi/Regeneron Pharmaceuticals
12.1.1. Drug Description
12.1.2. Regulatory Milestones
12.1.3. Other Developmental Activities
12.1.4. Pivotal Clinical Trial
12.1.5. Ongoing Current Pipeline Activity
12.2. Repatha (Evolocumab/AMG 145): Amgen
12.2.1. Drug Description
12.2.2. Regulatory Milestones
12.2.3. Other Developmental Activities
12.2.4. Pivotal Clinical Trial
12.2.5. Ongoing Current Pipeline Activity
12.3. Leqvio (Inclisiran): Novartis/Alnylam Pharmaceuticals
12.3.1. Drug Description
12.3.2. Regulatory Milestones
12.3.3. Other Developmental Activities
12.3.4. Pivotal Clinical Trial
12.3.5. Ongoing Current Pipeline Activity
13. Emerging Therapies
13.1. LIB003 (Lerodalcibep): LIB Therapeutics
13.1.1. Drug Description
13.1.2. Clinical Development
13.1.3. Safety and Efficacy
13.2. AZD8233 (ION449): AstraZeneca and Ionis Pharmaceuticals
13.2.1. Drug Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.3. Cepadacursen sodium (CIVI-007): CiVi Biopharma
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Safety and Efficacy
14. PCSK9 inhibitors: 7 Major Market Analysis
14.1. Key Findings
14.2. Market Outlook
14.3. Market of PCSK9 Inhibitors (PCSK9i)
14.4. Market Size of PCSK9 inhibitors
14.4.1. Total Market Size of PCSK9 inhibitors
14.4.2. Market Size of PCSK9 inhibitors by Therapies (Treatment and Secondary Prevention)
15. Market Access and Reimbursement
16. KOL Views
17. Market Drivers
18. Market Barriers
19. SWOT Analysis
20. Unmet Needs
21. Appendix
22. Publisher Capabilities
23. Disclaimer
24. About the Publisher
For more information about this report visit https://www.researchandmarkets.com/r/e4bc6x
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900